Genetic counselors are trying once again to gain Medicare recognition through this bill, so they can bill for their services.

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.

The startup aims to create a platform for treating extremely rare genetic mutations, armed with CRISPR advances and new regulatory pathways.

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.

NEW YORK – Mdxhealth and the University of Oxford will test whether the firm's Genomic Prostate Score (GPS) assay can predict disease progression and treatment outcomes in prostate cancer patients, ...

NEW YORK – Cartography Biosciences said on Tuesday it will collaborate with Pfizer to use its drug discovery platforms to identify tumor-selective antigens for an undisclosed cancer indication. Under ...

With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.